Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421669 | 0.87 | ALDH1A1 (0.34) | — | |
| SCHEMBL22097553 | 0.81 | IDO1 (0.33) | IDO1CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL4190146 | 0.78 | PDE2A (0.42) | IDO1CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL29256552 | 0.74 | PDE2A (0.51) | CYP2D6CYP3A4SLC6A4SLC6A3KCNH2 | |
| SCHEMBL29256553 | 0.74 | PDE2A (0.51) | CYP2D6CYP3A4SLC6A4SLC6A3KCNH2 | |
| SCHEMBL28773626 | 0.74 | IDO1 (0.34) | IDO1CYP1A2 | |
| SCHEMBL19334270 | 0.73 | SLC6A2 (0.33) | IDO1CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL4298647 | 0.72 | ADRB2 (0.56) | IDO1CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL12974095 | 0.72 | GABRA1 (0.46) | IDO1CYP3A4SLC6A2HIF1ABLM | |
| SCHEMBL28773732 | 0.72 | IDO1 (0.33) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902394-B2 | Calcilytic compounds | GLAXOSMITHKLINE LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100029782-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2120898-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077009-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029782-A1 | Calcilytic Compounds | CALCR, CALCA, CALCB | IDO1 4470/4885CYP2D6 648/4885CYP3A4 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.